Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant changes » significant challenge (Expand Search)
changes decrease » larger decrease (Expand Search), largest decrease (Expand Search), change increases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant changes » significant challenge (Expand Search)
changes decrease » larger decrease (Expand Search), largest decrease (Expand Search), change increases (Expand Search)
-
1141
Annual change in low-prevalence (orange) and hotspot (red) implementation units (IUs).
Published 2025Subjects: -
1142
-
1143
-
1144
-
1145
-
1146
-
1147
Changes in the white blood cell count.
Published 2025“…The leukocyte and neutrophil counts of the patients in the bone pain group were significantly higher than those of the patients in the no bone pain group, P(WBC) = 0.001, P(ANC) = 0.002.…”
-
1148
-
1149
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
1150
-
1151
-
1152
-
1153
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
1154
Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
1155
-
1156
-
1157
-
1158
-
1159
-
1160
Detailed analysis of the patellofemoral interactions after OWHTO in Knee 01.
Published 2025Subjects: